Latigo Biotherapeutics (LTGO)
Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.
$20.09
vs last close−0.73 (−3.49%)
Something off on this page? Send us feedback.
EPSReportedEstimate
———————Sep '26
Reported———————−$0.65
Estimate———————−$0.62
Surprise———————−5.4%
RevenueReportedEstimate
———————Sep '26
Reported————————
Estimate————————
Surprise————————
History
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.62 | −$0.65 | −5.4% |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | −$0.62 | −$0.65 | −5.4% | — | — | — | +2.5% |